Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis

Biologics: Targets and Therapy

Volumn 7, Issue 1, 2013, Pages 259-264

  Mathieu, Sylvain ^a,b   Couderc, Marion ^a,b   Glace, Baptiste ^a,b   Pereira, Bruno ^b,c   Tournadre, Anne ^a,b   Dubost, Jean Jacques ^a,b   Soubrier, Martin ^a,b  

^a Gabriel Montpied Hospital   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Arterial stiffness; Atherogenic index; Cardiovascular risk markers; Systemic inflammation

Indexed keywords

ABATACEPT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CHOLESTEROL; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEFLUNOMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTERIAL STIFFNESS; ARTICLE; ATHEROGENIC INDEX; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DRUG EFFECT; DRUG RESPONSE; DYSLIPIDEMIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; PROTEIN BLOOD LEVEL; PULSE WAVE; RHEUMATOID ARTHRITIS;

EID: 84889057402     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S52003     Document Type: Article

References (31)

1. Meune C, Touzé E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology. 2009;48(10):1309-1313.
2. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis. 2011;70(1): 8-14.
3. Van Doornum S, McColl G, Jenkins A, Green DJ, Wicks IP. Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum. 2003;48(1):72-80.
4. Forte L, Cimmino G, Loffredo F, etal. C-reactive protein is released in the coronary circulation and causes endothelial dysfunction in patients with acute coronary syndromes. Int J Cardiol. 2011;125(1):7-12.
5. Solomon DH, Kremer J, Curtis JR, etal. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis. 2010;69(11): 1920-1925.
6. Sandoo A, Veldhuijzen van Zanten JJ, Metsios GS, Carroll D, Kitas GD. Vascular function and morphology in rheumatoid arthritis: a systematic review. Rheumatology (Oxford). 2011;50(11):2125-2139.
7. Mathieu S, Pereira B, Dubost JJ, Lusson JR, Soubrier M. No significant change in arterial stiffness in RA after 6months and 1 year of rituximab treatment. Rheumatology. 2012;51(6):1107-1111.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
9. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockcroft JR. Reproducibility of velocity and augmentation index measured by analysis. J Hypertens. 1998;16:2079-2084.
10. Boutouyrie P, Vermeersch SJ. Reference values for arterial stiffness' collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: "establishing normal and reference values" European Heart Journal. 2010;31(19):2338-2350.
11. Laurent S, Cockcroft J, van Bortel L, et al. European network for non-invasive investigation of large arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. European Heart Journal. 2006;27(21):2588-2605.
12. Dulai R, Perry M, Twycross-Lewis R, Morrissey D, Atzeni F, Greenwald S. The effect of tumor necrosis factor-α antagonists on arterial stiffness in rheumatoid arthritis: a literature review. Semin Arthritis Rheum. 2012;42(1):1-8.
13. Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheum. 2011;38(10):2169-2171.
14. Protogerou AD, Zampeli E, Fragiadaki K, Stamatelopoulos K, Papamichael C, Sfikakis PP. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis. 2011;219(2):734-736.
15. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214-1224.
16. Characteristics of tocilizumab. European Medicines Agency; 2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000955/WC500054890.pdf. Accessed November 9, 2013.
17. Bannwarth B, Richez C. Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf. 2011;10(1):123-131.
18. Kawashiri SY, Kawakami A, Yamasaki S, etal. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int. 2011;31(4):451-456.
19. Hansel B, Bruckert E. [Lipid profile and cardiovascular risk in patients with rheumatoid arthritis: Effect of the disease and of drug therapy]. Ann Endocrinol (Paris). 2010;71(4):257-263. French.
20. Popa C, Netea MG, Radstake T, etal. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis. 2005;64(2):303-305.
21. Dahlqvist SR, Engstrand S, Berglin E, Johnson O. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. Scand J Rheumatol. 2006;35(2):107-111.
22. Vis M, Nurmohamed MT, Wolbink G, etal. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol. 2005;32(2):252-255.
23. Allanore Y, Kahan A, Sellam J, Ekindjian OG, Borderie D. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta. 2006;365(1-2): 143-148.
24. Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2006;33(5):921-923.
25. Soubrier M, Jouanel P, Mathieu S, etal. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine. 2008;75(1):22-24.
26. Payet S, Pereira B, Soubrier M, Mathieu S. The effects of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum. 2012;41(4):e4-e5.
27. Daïen CI, Duny Y, Barnetche T, Daurès JP, Combe B, Morel J. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis. 2012;71(6):862-868.
28. van Sijl AM, Peters MJ, Knol DL, etal. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum. 2011;41(3):393-400.
29. Kerekes G, Soltész P, Dér H, etal. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol. 2009;28(6):705-710.
30. Schimmel EK, Yazici Y. Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience. Clin Exp Rheumatol. 2009;27(3):446-451.
31. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63(4): 522-529.